tbuckley/cabot-search huggingface dataset:
Abstract P208: Racial Differences in Stroke Severity and Outcomes in Female Acute Ischemic Stroke Patients
Authors: Amelia K Boehme, James E Siegler, Karen C Albright, Dominique J Monlezun, Erica M Jones, T. Mark Beasley, James C Grotta, Sean I Savitz, Nicole R Gonzales, Sheryl Martin-Schild
Journal: Circulation (2013)

Background: Previous research has indicated that women and Blacks have worse outcomes following acute ischemic stroke (AIS). Little research has been done to investigate the influence of race in the presentation and outcome specifically among women with AIS. Methods: AIS patients presenting to two centers in the Stroke Belt (2004-2011) were identified by prospective registries. Men, women who did not identify as Black or White, and in-hospital strokes were excluded. Patient demographics, clinical characteristics, admission National Institutes of Health Stroke Scale (NIHSS) scores, favorable discharge disposition (home or inpatient rehab), time from last seen normal to ED arrival, and functional discharge outcome as measured by the modified Rankin Scale (mRS) were investigated. Patients were divided into 3 groups: (1) not treated with IV t-PA, (2) treated with IV t-PA within 3 hours of symptom onset, and (3) treated with IV t-PA beyond 3 hours. Results: Of the 8763 patients screened, 2217 women met the study criteria (59% White). White women were older (72 vs. 64; p&lt;0.0001), had higher percentage of atrial fibrillation (24% vs. 11%; p&lt;0.0001), lower percentage of diabetes (30% vs. 40%, p&lt;0.0001), lower percentage of hypertension (73% vs. 84%; p&lt;0.0001) and had a higher baseline NIHSS (9 vs. 7; p=0.0045) Administration of tPA was significantly less among Black women (36% Whites vs. 27% Blacks, p&lt;0.0001). White women are at increased odds of receiving tPA treatment (OR=1.43, 95%CI 1.17-1.75, p=0.0005), and remain at increased odds after adjusting for age, baseline NIHSS, time from last seen normal and glucose (OR 1.42, 95% CI 1.11-1.81, p=00044). Despite the significant difference in treatment with IV tPA, White women had increased odds of having a poor functional outcome (OR=1.2, 95% CI 1.02-1.439,p=0.0250) and unfavorable discharge disposition (OR 1.4, 95% CI 1.18-1.67, p=0.0001), but stratifying by tPA treatment groups, race was not found to be predictive of outcome after adjusting for known confounders (i.e., age, glucose, baseline NIHSS, time from last seen normal). Discussion: Unlike data from previous studies, Black women who presented to these two centers with AIS had less severe neurologic deficits on presentation compared to their White counterparts. Despite differences in the proportion of Blacks and Whites treated with IV tPA, race was not significantly associated with outcome. In our study, age and stroke severity_not race_were the primary predictors for poor outcome.
John McCrae (1872–1918)
Authors: David P. Boyd
Journal: New England Journal of Medicine (1959)

THE memorial window to John McCrae in the Medical Building at McGill University reads, "Pathologist, Poet, Physician, Soldier, Man among Men." Each facet of this remarkable man's life may be briefly surveyed with pleasure and with profit, although to speculate on which aspect meant most to him is idle. He doubtless could not have answered the question himself, just as the Autocrat could not tell Osler which pleased him more — to have contributed to the knowledge of childbed fever or to have written The Chambered Nautilus.PathologistThe first pathologist of the Montreal General Hospital was William Osler. . . .
A phase III randomized study of paclitaxel and trastuzumab versus paclitaxel alone for early stage, ER and PR receptor negative and HER2-positive breast cancer as adjuvant treatment
Authors: M.K. Singhal, A. Kapoor, S. Narayan, S. Maharia, R.K. Nirban, S.K. Beniwal, H.S. Kumar
Journal: Annals of Oncology (2015)
Outpatient Administration Of Hyper-CVAD Chemotherapy For Acute Lymphoblastic Leukaemia / Lymphoma Is Safe and Associated With Similar Toxicity Compared To Inpatient Delivery
Authors: Emad Uddin Abro, Kirk Morris, Georgina Hodges, Jason P Butler, Cameron Curley, Elango Subramonia Pillai, Glen A Kennedy
Journal: Blood (2013)
Autoradiographic Analysis of Uptake of Tritiated Thymidine and S&lt;sup&gt;35&lt;/sup&gt; Cystine by Cultured Human Cervical Expiants Undergoing Metaplasia
Authors: Reid, Bevan L.
Journal: JNCI Journal of the National Cancer Institute (1964)

Journal Article Autoradiographic Analysis of Uptake of Tritiated Thymidine and S35 Cystine by Cultured Human Cervical Expiants Undergoing Metaplasia Get access Bevan L. Reid Bevan L. Reid Queen Elizabeth II Research Institute for Mothers and Infants, University of Sydney, Sydney, N.S.W., Australia Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 32, Issue 5, May 1964, Pages 1059–1073, https://doi.org/10.1093/jnci/32.5.1059 Published: 01 May 1964 Article history Received: 08 October 1963 Published: 01 May 1964
Cardiovascular MRI is better than standard scan, say researchers
Authors: Jacqui Wise
Journal: BMJ (2016)

Cardiovascular magnetic resonance (CMR) is a stronger predictor of major adverse cardiovascular events than single photon emission computed tomography, a five year follow-up published in the Annals of Internal Medicine has found.1

CMR is a magnetic resonance imaging scan that focuses on the area around the heart, but, unlike single photon emission computed …
Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies
Authors: Barry J. Maron, Ethan J. Rowin, Susan A. Casey, Mark S. Link, John R. Lesser, Raymond H.M. Chan, Ross F. Garberich, James E. Udelson, Martin S. Maron
Journal: Journal of the American College of Cardiology (2015)
Parenting as Primary Prevention
Authors: Ellen C. Perrin, Laurel K. Leslie, Thomas Boat
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
Authors: Luca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, Ling-Ming Tseng, Mei-Ching Liu, Ana Lluch, Elżbieta Starosławska, Juan de la Haba-Rodriguez, Seock-Ah Im, Jose Luiz Pedrini, Brigitte Poirier, Paolo Morandi, Vladimir Semiglazov, Vichien Srimuninnimit, Giulia Valeria Bianchi, Domenico Magazzù, Virginia McNally, Hannah Douthwaite, Graham Ross, Pinuccia Valagussa
Journal: The Lancet Oncology (2016)
Nocturnal Hypoglycemia and Physical Activity in Children With Diabetes: New Insights by Continuous Glucose Monitoring and Accelerometry
Authors: Sara Bachmann, Melanie Hess, Eva Martin-Diener, Kris Denhaerynck, Urs Zumsteg
Journal: Diabetes Care (2016)

Nocturnal hypoglycemia often remains unrecognized (1). Detection and prevention of such events is, however, important: repeated nocturnal hypoglycemia might compromise daytime performance and counterregulation (2).

Hypoglycemia incidence has been reported to be much higher in children than in adults (3). Therefore, identification of nocturnal hypoglycemia is of special importance in clinical pediatric diabetology.

The aim of this study was to evaluate the frequency and duration of nocturnal hypoglycemia in children with diabetes and to identify risk factors for such events. As hypoglycemia is associated with exercise, the influence of physical activity was studied by combining glucose measurements with accelerometry.

A total of 60 children with type 1 diabetes for >6 months were included, and data from 51 subjects (29 male, 22 female; aged 2–17 years; HbA1c 8.1 ± 1.5% [65.4 ± 16.4 mmol/mol]) were complete. A total of 36 subjects received multiple injection therapy (MIT), and 15 subjects were on continuous …
PWE-312 The surgical management of isolated paraaortic lymph node recurrence following colorectal cancer resection: a case series and systematic review
Authors: EM Burns, A Ardakani, A Loh, R Glynne-Jones, C Elton
Journal: Gut (2015)

<h3>Introduction</h3> Isolated paraaortic lymph-node recurrence (IPLNR) accounts for one percent of recurrent disease following colorectal cancer resection. We present a case series of patients in whom paraaortic lymphadenectomy for IPLNR following colorectal cancer was performed along with a systematic review of existing literature. <h3>Method</h3> Patients who underwent a metachronous paraaortic lymphadenectomy for IPLNR were identified retrospectively from a prospectively collected colorectal cancer database between 2005 and 2011. Demographics, surgical morbidity and long term outcome and survival were extracted. A systematic review of the literature was undertaken using three electronic databases, PUBMED, EMBASE and Google scholar following PRISMA guidelines. Additional papers were extracted from manual searches of the references. <h3>Results</h3> From the local colorectal cancer database four patients who underwent metachronous IPLNR lymphadenectomy were included. The median follow up of these patients was 20.3 months (interquartile range (IQR) 12.5–29.6 months). There were no perioperative morbidity or deaths in this cohort. One out of four patients (25%) experienced a rerecurrence at 31 months and was treated with CyberKnife<sup>TM</sup>. All patients were still alive at the end of the follow up period. Following systematic review, seven published studies were analysed. Further analysis included the four patients in this case series and 110 patients identified through systematic review (n = 114). Overall, the median follow up following surgery was 29.5 months (IQR 26.8–31.0 months). Of these patients, there were no perioperative deaths and 22 patients (19%) experienced major perioperative complications including bleeding, ileus and wound infection. Recurrences following lymphadenectomy were experienced by 64% (73/114) of patients. In those studies (5 studies) that reported 5 year overall survival, the overall survival was 50% (51/102). <h3>Conclusion</h3> The morbidity and mortality following lymphadenectomy for IPLNR is low. In carefully selected patients surgical intervention for IPLNR may be associated with improved longer term survival similar to the results seen after hepatic resection. <h3>Disclosure of interest</h3> None Declared.
A Randomized Phase Ii Study of Paclitaxel-Carboplatin-Bevacizumab (Pcb) with or Without Nitroglycerin Patches (Ntg) in Patients (Pts) with Stage Iv Non-Squamous-Non-Small Cell Lung Cancer (Ns-Nsclc)(Nvalt 12), Impact of Circulating Vascular Endothelial Growth Factor (Vegf) Levels
Authors: A.C. Dingemans, H.J.M. Groen, G. Herder, E.F. Smit, S. Burgers, J. Stigt, P. De Goeije, O. Dalesio, B. Biesma, V. van der Noort, J.G. Aerts
Journal: Annals of Oncology (2014)
No reason not to treat
Authors: H. H Balfour
Journal: BMJ (1995)

no evidence at present to suggest that resistant strains of varicella zoster virus will occur in the immuno- competent community with antiviral use, but this will need to be monitored.Resistance has occurred rarely in immunocompromised patients with varicella zoster virus infection; prolonged viral replication in these patients provides an optimum environment for selection of resistant strains.The mildness and self limiting nature of chickenpox is confirmed by the placebo groups in the American studies.Though an argument can be made for treating secondary and tertiary cases and adults with acyclovir as well as any immunocompromised patient, the modest clinical benefit from what would be a very costly programme do not support the routine treatment of chickenpox in normal healthy children.1 Preblud SR.Age specific risks of varicella complications.
A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer.
Authors: J. Liu, G. F. Fleming, S. M. Tolaney, M. J. Birrer, R. T. Penson, S. T. Berlin, C. Whalen, K. Tyburski, K. Matijevich, E. Kasparian, M. Roche, H. Lee, E. P. Winer, S. P. Ivy, U. Matulonis
Journal: Journal of Clinical Oncology (2011)

5028 Background: Olaparib is an orally-bioavailable PARP inhibitor with activity as monotherapy in ovarian and breast cancer; cediranib is a multitargeted kinase inhibitor of VEGFR-1/2/3 and c-kit. PARP-inhibition has anti-angiogenic effects in the preclinical setting; however, the effect of combined therapy against PARP and angiogenesis has not been reported. We investigated the toxicities and recommended phase 2 dosing (RP2D) of the combination of cediranib and olaparib (NCT01116648). Methods: Cediranib tablets daily and olaparib capsules BID were administered PO in cohorts of 3 pts in a standard 3+3 Phase 1 design. Eligibility included pts with recurrent ovarian or metastatic triple-negative breast cancer. Pts had measurable disease by RECIST 1.1 or met GCIG CA125 criteria. No prior anti-angiogenic therapies in the recurrent setting or prior PARP-inhibitors were allowed. Results: 18 pts (13 ovarian, 5 breast) have been accrued thus far to 4 dose levels: DL0: cediranib (C) 20mg daily/olaparib (O) 100mg BID (3 pts); DL1: C 20mg daily/O 200mg BID (3 pts); DL2: C 30mg daily/O 200mg BID (6 pts); DL3: C 30mg daily/O 400mg BID (6 pts). 2 DLTs (1 gr 4 neutropenia ≥ 4d; 1 gr 4 thrombocytopenia) were seen at the highest dose level. Other gr 3/4 toxicities include gr 4 neutropenia (1 pt), hypertension (3 pts), fatigue (3 pts), anorexia (1 pt), nausea (1 pt), and asymptomatic PE (1 pt). The RP2D is anticipated to be cediranib 30mg daily/olaparib 200mg BID. 10 ovarian and 1 breast cancer pt were known BRCA mutation carriers. Ovarian pts had a median of 2 prior lines of therapy (range 1-9); breast pts had 3 (2-5). Best response for 9 evaluable ovarian cancer pts at time of data capture include 1 cCR (DL1), 3 cPR (2 DL0, 1 DL3), 1 uPR (DL2), 3 cSD (1 DL1, 2 DL3), and 1 uSD (DL2). Best response for 5 evaluable breast cancer pts include 1 cSD (DL1), 2 uSD (1 DL0, 1 DL2), and 2 PD (2 DL3). Conclusions: The combination of cediranib and olaparib has hematologic toxicity DLTs and anticipated class toxicities, with preliminary evidence of efficacy in the tested population, including a 56% unconfirmed response rate in ovarian cancer patients.
Evaluation of the enterovirus laboratory surveillance system in Denmark, 2010 to 2013
Authors: Orla Condell, Sofie Midgley, Claus Bohn Christiansen, Ming Chen, Xiaohui Chen Nielsen, Svend Ellermann-Eriksen, Mette Mølvadgaard, Kristian Schønning, Silje Vermedal Hoegh, Peter Henrik Andersen, Marianne Voldstedlund, Thea Kølsen Fischer
Journal: Eurosurveillance (2016)

The primary aim of the Danish enterovirus (EV) surveillance system is to document absence of poliovirus infection. The conflict in Syria has left many children unvaccinated and movement from areas with polio cases to Europe calls for increased awareness to detect and respond to virus-transmission in a timely manner. We evaluate the national EV laboratory surveillance, to generate recommendations for system strengthening. The system was analysed for completeness of viral typing analysis and clinical information and timeliness of specimen collection, laboratory results and reporting of clinical information. Of 23,720 specimens screened, 2,202 (9.3%) were EV-positive. Submission of cerebrospinal fluid and faecal specimens from primary diagnostic laboratories was 79.5% complete (845/1,063), and varied by laboratory and patient age. EV genotypes were determined in 68.5% (979/1,430) of laboratory-confirmed cases, clinical information was available for 63.1% (903/1,430). Primary diagnostic results were available after a median of 1.4 days, typing results after 17 days, detailed clinical information after 33 days. The large number of samples typed demonstrated continued monitoring of EV-circulation in Denmark. The system could be strengthened by increasing the collection of supplementary faecal specimens, improving communication with primary diagnostic laboratories, adapting the laboratory typing methodology and collecting clinical information with electronic forms.
Allergenicity and safety of recombinant human C1 esterase inhibitor in patients with allergy to rabbit or cow's milk
Authors: Mignon T. van den Elzen, Harmieke van Os-Medendorp, Heike Röckmann-Helmbach, Els van Hoffen, Ans F.M. Lebens, Helma van Doorn, Rob J.B. Klemans, Carla A.F.M. Bruijnzeel-Koomen, C. Erik Hack, Leonard Kaufman, Anurag Relan, André C. Knulst
Journal: Journal of Allergy and Clinical Immunology (2016)
Drug Regulation and Pricing — Can Regulators Influence Affordability?
Authors: Hans-Georg Eichler, Hugo Hurts, Karl Broich, Guido Rasi
Journal: New England Journal of Medicine (2016)

Regulation may contribute to high drug costs, but there are several ways in which regulators at the European Medicines Agency believe they can contribute to keeping drug spending sustainable, beginning with approving genetics and biosimilars more rapidly.
Developing a score chart to improve risk stratification of patients with colorectal adenoma
Authors: Else-Mariëtte van Heijningen, Iris Lansdorp-Vogelaar, Frank van Hees, Ernst Kuipers, Katharina Biermann, Harry de Koning, Marjolein van Ballegooijen, Ewout Steyerberg
Journal: Endoscopy (2016)

<b>Background and study aims:</b> Current surveillance guidelines risk stratify patients with adenoma by using only one or two factors: adenoma multiplicity or presence of an advanced adenoma characteristic. Combinations of adenoma characteristics are not considered, which limits the predictive value of these guidelines. The aim of the study was to develop a scoring system for more refined risk stratification of patients with adenoma. <b>Patients and methods:</b> The Dutch Pathology Registry (PALGA) was used to identify newly diagnosed patients with adenoma in 10 Dutch hospitals between 1988 and 2002. Medical records were reviewed until 1 December 2008 for follow-up. Logistic regression analysis was used to assess patient- and adenoma-related predictors of metachronous advanced neoplasia. The prediction model was validated by bootstrapping and cross-validation. A score chart was developed based on identified adenoma-related predictors. The discriminative ability of the prediction model was compared with currently used risk stratifications in surveillance guidelines. <b>Results:</b> A total of 2914 patients with adenoma were included (mean age 61 years; 55 % male). The score chart consisted of characteristics that contributed 1 point (size ≥ 10 mm, villous histology, proximal location, having 2 – 4 adenomas) or 2 points (having ≥ 5 adenomas). A patient's adenoma risk score could range from 0 to 5 points. A score of 5 for a 75-year-old man implied a 5-year risk of advanced neoplasia of 46 %. The discriminative ability of the model was moderate (c-statistic 0.712) but better than risk stratifications in current international guidelines, which had c-statistics of 0.642 – 0.674. <b>Conclusion:</b> A score chart that combines adenoma-related predictors of advanced colorectal neoplasia optimized the risk stratification of patients with adenoma for appropriate surveillance colonoscopy intervals.
Growth Characteristics of a Transferable Acute Leukemia in Rats 2
Authors: D. Hoelzer
Journal: JNCI Journal of the National Cancer Institute (1973)

After intravenous transfer of leukemia cells, growth of acute myelomonocytic leukemia was mainly in the bone marrow and spleen of rats. All organs became involved later, particularfy when many leukemia cells appeared in the peripheral blood. After injection of 107 leukemia cells, doubling time of absolute numbers of blast cells in the bone marrow was about 30 hours, and of the leukemia blast cells in peripheral blood was shorter, with a minimum of about 6 hours. However, neither estimate represents the true generation time of the leukemia blast cells, because loss of cells from bone marrow and influx from various organs to the blood occurred. The course of the leukemia was predictable, with the easily determined leukocyte count and spleen weight reliable indicators of its severify. There was a strong correlation between growth of the leukemia and the number of cells injected: A time lag of 25–30 hours occurred in the appearance of leukemia cells in the peripheral blood for each tenfold reduction in the number of cells injected, followed by a similar sigmoid curve for all groups. Neither age (4 wk-1 yr) nor weight (55–400 g) significantly aHected the growth pattern of the leukemia. Survival ranged from 6 to 7 days after transfer of 107 leukemia cells to 12–13 days after 102 leukemia cells.
Anti–miR-148a regulates platelet FcγRIIA signaling and decreases thrombosis in vivo in mice
Authors: Yuhang Zhou, Shaji Abraham, Pierrette Andre, Leonard C. Edelstein, Chad A. Shaw, Carol A. Dangelmaier, Alexander Y. Tsygankov, Satya P. Kunapuli, Paul F. Bray, Steven E. McKenzie
Journal: Blood (2015)